STOCKBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Updated 2026-05-03
Here’s whether Exelixis Inc (EXEL) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+0.66% over 10 days); RSI 44 — healthy momentum range; strong 1-year return of +12.3%. Currently 12.0% off its 52-week high. Score: +6/7.
EXEL is in a confirmed uptrend, trading above both its 50-day ($43.30) and 200-day ($41.68) moving averages. An RSI of 44.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +12.3% compares to +24.4% for SPY (trailed the market by 12.1%).
$10,000 invested 1 year ago→ $11,232 today
vs. S&P 500 (SPY) — same period trailed market by 12.1%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($41.68)
✓Above 50-day MA ($43.30)
✓RSI(14) neutral zone (30–70) — currently 44.4
✓Positive return (+12.3%)
!Within 10% of period high (−12.0%)
Period Range $43.68
$33.76$49.62
RSI (14) 44.4
0 · OversoldOverbought · 100
Key Metrics
Price$43.68
Period Return+12.3%
Period High$49.62
Period Low$33.76
Drawdown−12.0%
MA-50$43.30
MA-200$41.68
RSI (14)44.4
Avg Volume (30d)2.5M
vs. SPYtrailed by 16.7%
Return Rank#599 of 1245
Trend Signals
Price is above the 200-day moving average ($41.68)